June 16, 2017
The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference revealed promising data supporting two new drug classes for the treatment of psoriatic arthritis (PsA).
New agents working on different inflammatory aspects of PsA are needed in the treatment of PsA patients living with this chronic immune-mediated disease, which involves both joint and skin symptoms.
In the first study, in patients with active PsA who had not previously been prescribed an anti-TNF treatment, tofacitinib (an oral Janus kinase inhibitor under investigation for the treatment of PsA), was superior to placebo in ACR20 response rates and change from baseline in the HAQ-DI score at 3 months. Tofacitinib demonstrated superiority to placebo as early as week 2, and this was maintained for 12 months. No new safety risks were identified compared to previous studies in other indications.1
In the second study, in patients with active PsA and 3% or more of their body surface area affected by plaque psoriasis despite current or previous treatment with standard-of-care therapies, including anti-TNF treatments, guselkumab demonstrated significant improvement in joint symptoms, physical function, psoriasis, enthesitis , dactylitis and quality of life. Guselkumab, a fully human monoclonal antibody targeting IL-23, in this Phase 2 study for the treatment of PsA, was well tolerated with no unexpected safety findings in this patient population.2 Guselkumab is now being pursued in a Phase 3 development programme for psoriatic arthritis.
Tofacitinib Phase 3 Results positive for treating PsA
At month 3, tofacitinib 5 and 10 mg twice-daily showed a statistically significant improvement compared to placebo as measured by the ACR20 response (p?0.05 and p<0.0001 respectively), and change from baseline in the HAQ-DI score (p?0.05 and p<0.001).
"Despite the differences emerging in the pathophysiology of PsA and rheumatoid arthritis, tofacitinib, which works on many different cytokines, shows efficacy in the treatment of both conditions," said lead author Professor Philip J. Mease from the Swedish-Providence St. Joseph Health Systems and University of Washington School of Medicine, Seattle, US. "Since tofacitinib is a tablet and not an injection, once it receives regulatory approval, it is likely to be popular with both physicians and patients," he added.
Tofacitinib 5 and 10 mg twice-daily was superior to placebo for ACR20 response rates at week 2 (p<0.001 and p<0.0001 respectively) with responses maintained to 12 months. Greater efficacy was also seen for adalimumab vs. placebo.
More than 91% of patients were radiographic non-progressors at 12 months. Safety findings were similar between the treatment groups at 12 months. The most common adverse events were upper respiratory tract infection (7.5-10.6%), nasopharyngitis (7.5-11.5%) and headache (3.8-10.6%).
Eligible patients in this randomised, placebo- and active-controlled, 12-month Phase 3 trial had a PsA diagnosis for at least 6 months, fulfilled CASPAR criteria , had active arthritis (at least 3 tender/painful and at least 3 swollen joints) and active plaque psoriasis at screening, inadequate response to at least 1 csDMARD , and were tumour necrosis factor-inhibitor (TNFi)-nave.
422 patients were randomised 2:2:2:1:1 to tofacitinib 5 or 10 mg twice daily, adalimumab 40 mg subcutaneous injection every 2 weeks, or placebo (advancing to tofacitinib 5 or 10 mg twice-daily at 3 months). Stable treatment with 1 csDMARD was required. 96.9% of patients were white and 53.3% were female; mean age was 47.9 years. 96.2% and 88.4% of patients completed 3 and 12 months respectively.
Guselkumab improved PsA symptoms, physical function and quality of life
In this Phase 2a study, significantly more guselkumab-treated patients achieved ACR 20/50/70 responses and Psoriasis Area Severity Index (PASI) 75/90/100 responses at week 24. Nearly 40% of patients in the active group, vs. 6.3% in the placebo arm, achieved PASI 100 (completely clear skin) at week 24.
"Guselkumab, which targets IL-23, appears to be a promising new treatment of PsA," said lead author Professor Atul Deodhar from Oregon Health & Science University, Portland, US. "Although anti-TNF treatments have revolutionised the management of psoriatic arthritis, new next-generation therapies are needed in the treatment of this disease," he added.
As early as 4 weeks into treatment, 21% in the guselkumab group had a significant treatment effect on ACR20 response, compared to zero in the placebo group (p<0.001). The ACR response in the active arm increased with time, with 58% of subjects reaching a 20% improvement in joint symptoms at week 24, versus 18.4% of those on placebo (p<0.001). Fourteen percent of patients on guselkumab achieved ACR70, versus 2% on placebo, at week 24 (p=0.023).
Resolved enthesitis occurred in 29.0% of those patients with enthesitis at baseline in the placebo group at week 24, versus 56.6% on guselkumab (p=0.012). The percentage resolution from baseline to week 24 for dactylitis (in those patients with dactylitis at baseline) was 17.4% of patients on placebo, versus 55.2% on guselkumab (p<0.001). And the percentage of patients achieving minimal disease activity at week 24 was 2% for placebo compared to 23% in the guselkumab group (p=0.001).
Patients in the active arm also seemed to experience mental benefits, with significantly higher scores on the SF-36 mental component summary (p=0.002), in addition to significantly higher physical component scores (p<0.001).
Guselkumab was well tolerated; through week 24, the proportion of patients with at least 1 adverse event was comparable between the two groups (guselkumab 36.0% vs. placebo 32.7%). Infections were the most common adverse events (guselkumab 17.0% vs. placebo 20.4%). The researchers reported no serious infections, cancer or death during the 24 weeks of the study.
This Phase 2a, randomised, double-blind, placebo-controlled multicentre study included 149 active PsA patients. Patients had psoriasis plaques covering three percent or more of their body surface area, despite standard-of-care treatment, which in some patients included anti-TNF agents. In a 2:1 ratio, patients received either 100 mg guselkumab given subcutaneously, or placebo at baseline and week four; then, every eight weeks through week 44.
Patients in both arms who had less than a 5 percent improvement from baseline in swollen and tender joint counts by week 16 could qualify for early escape and switch to open-label therapy with ustekinumab. All remaining placebo patients crossed over to the guselkumab arm at week 24.
Baseline demographics and ACR component measures were generally similar between the two groups. Four (8.2%) of the patients in the placebo group and 9 (9.0%) of patients in the guselkumab group had been previously exposed to an anti-TNF agent
Explore further: Tofacitinib ups rheumatoid arthritis treatment response
(HealthDay)The addition of tofacitinib to rheumatoid arthritis (RA) treatment regimens improves patient response to non-biologic disease-modifying antirheumatic drugs (DMARDs), according to a study published in the Aug. ...
A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX). Results of the 12-month ...
The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference have highlighted limitations in the current treatment of patients with Psoriatic Arthritis (PsA).
New data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses ...
Results of a Phase III study presented today at the EULAR 2011 Annual Congress show that at 6 months, 58.3 percent of patients who had previously not responded to treatment with DMARDs, achieved ACR20 response (a 20 percent ...
In a pivotal phase-3 clinical trial led by a Stanford University School of Medicine investigator, patients with psoriatic arthritis for whom standard-of-care pharmaceutical treatments have provided no lasting relief experienced ...
Stepping up to biologic therapy when methotrexate monotherapy fails offers minimal incremental benefit over using a combination of drugs known as triple therapy, yet incurs large costs for treating rheumatoid arthritis (RA). ...
New research from the University of Liverpool, published today in the journal npj Systems Biology and Applications, has identified 'cell messages' that could help identify the early stages of osteoarthritis (OA).
Osteoarthritis can potentially be prevented with a good diet and regular exercise, a new expert review published in the Nature Reviews Rheumatology reports.
Maintaining the supply of a molecule that helps to nourish cartilage prevented osteoarthritis in animal models of the disease, according to a report published in Nature Communications online May 11.
The results of a study led by Massachusetts General Hospital (MGH) investigators suggest that following a diet known to reduce the risk of hypertension and cardiovascular disease may also reduce the risk of gout. The team's ...
In a preclinical study in mice and human cells, researchers report that selectively removing old or 'senescent' cells from joints could stop and even reverse the progression of osteoarthritis.
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Follow this link:
New effective treatments for psoriatic arthritis patients - Medical Xpress - Medical Xpress
- The Compression Fracture of Thoracic Spine Due to Methotrexate-Associated Lymphoproliferative Disorder in Rheumatoid Arthritis: A Case Report - Cureus - February 15th, 2025
- Rheumatoid arthritis tied to cognitive decline in dementia - Medical Xpress - February 15th, 2025
- Tools and Devices to Improve Life and Mobility With Arthritis - U.S. News & World Report - February 15th, 2025
- Actor Adam Thomas Reveals How 'Eating Nothing But Meat and Eggs' is Easing his Arthritis Pain But These Are the Risks - Men's Health UK - February 15th, 2025
- New insights into the association between arthritis and overactive bladder in NHANES 20052020 - Nature.com - February 15th, 2025
- Rheumatoid Arthritis Treatment Market to Hit US$ 79.1 Billion - openPR - February 15th, 2025
- Psoriatic Disease, TNF Inhibitors, and Risk of Major Adverse Events - Medpage Today - February 15th, 2025
- The best treatments for arthritic knees if you want to avoid knee replacement surgery - The Telegraph - February 15th, 2025
- Early Launch Metrics Indicate UCBs Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthritis Market - GlobeNewswire - February 15th, 2025
- Rosnilimab shows promise in rheumatoid arthritis trial - Investing.com - February 15th, 2025
- 5 foods that keep your joints strong and healthy - Mint - February 15th, 2025
- If You Have Arthritis, This New Makeup Brand Is for You - Money Talks News - February 15th, 2025
- Lower Your Risk Of Rheumatoid Arthritis With These 5 Basic Habits - mindbodygreen - February 15th, 2025
- 'I treat top athletes with arthritis - cupboard staple ingredients are quite effective for pain and swelling' - GB News - February 15th, 2025
- AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment - Yahoo - February 15th, 2025
- Rheumatology enters the chat: research projects use AI and collaborative thinking to improve patient care - University of Alberta - February 15th, 2025
- In Patients with HS, a Closer Look at Stigmatization and Perceived Health Status - Medpage Today - February 15th, 2025
- Psoriatic Arthritis Treatment Market is Set To Fly High in Years to Come: AbbVie Inc., Amgen Inc., Johnson & - EIN News - February 15th, 2025
- Sandoz Rolls Out Rival Version Of AbbVie's Arthritis Drug Humira - BW Healthcare World - February 15th, 2025
- GSK To Bounce Regulatory Submissions For Experimental Arthritis Drug - BW Healthcare World - February 15th, 2025
- Living With Arthritis: Health Information Basics for You and Your ... - January 27th, 2025
- Rheumatoid Arthritis: Diagnosis, Treatment, and Steps to Take - January 27th, 2025
- Rheumatoid Arthritis | Health Topics | NIAMS - January 27th, 2025
- 6 Things to Know About Psoriatic Arthritis - Hartford HealthCare - January 27th, 2025
- MAPK4 inhibits the early aberrant activation of B cells in rheumatoid arthritis by promoting the IRF4-SHIP1 signaling pathway - Nature.com - January 27th, 2025
- Rheumatoid Arthritis Basics: Overview, Symptoms, and Causes - January 27th, 2025
- 8 Things You Should Do in Your 20s, 30s, and 40s to Prevent Joint Pain Later in Life - Self - January 27th, 2025
- 8 Natural Remedies to Relieve Join Pain and Improve Mobility - Health.com - January 27th, 2025
- East Texas vet tells what to watch for during cold weather in arthritic pets - KTRE - January 27th, 2025
- Research Shows a Link Between Inflammation in the Gut and Rheumatoid Arthritis - Health Central - January 27th, 2025
- Address to the Business Community Attend the Arthritis Foundation Event - TAPinto.net - January 27th, 2025
- The journey of 2-year-old with arthritis - PAHomePage.com - January 27th, 2025
- East Texas vet tells what to watch for during cold weather in arthritic pets - KLTV - January 27th, 2025
- Four tips for managing rheumatoid arthritis in the winter - Yahoo Lifestyle UK - January 27th, 2025
- Living with arthritis: Here's how diet, exercise, and daily habits can ease the pain - Moneycontrol - January 27th, 2025
- Sichuan wildlife park peddles tiger urine, claiming efficacy for rheumatoid arthritis, other conditions - Global Times - January 27th, 2025
- Non-surgical option to ease knee arthritis - The Week - January 27th, 2025
- Ease arthritis pain by adding 1 juice to your diet - Surrey Live - January 27th, 2025
- Four tips for managing rheumatoid arthritis in the winter - Yahoo News UK - January 27th, 2025
- Drinking one juice can ease arthritis pain, studies reveal - Daily Record - January 27th, 2025
- Annual Health Observances | NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) - October 6th, 2024
- Obesity dampens rheumatoid arthritis treatment effectiveness, satisfaction - Healio - October 6th, 2024
- Patient Perspectives: Finding Grace While Living With Rheumatoid Arthritis - Rheumatology Advisor - October 6th, 2024
- Rheumatoid arthritis tied to heavy economic and human burdens - Medical Xpress - October 6th, 2024
- Dual therapy can have synergistic effect in difficult-to-treat inflammatory diseases - Healio - October 6th, 2024
- Hand-Held Scanner Could Transform Cancer and Arthritis Diagnosis - Technology Networks - October 6th, 2024
- Medical imaging breakthrough could transform cancer and arthritis diagnosis - University College London - October 6th, 2024
- Citryll and leading rheumatology centres receive - GlobeNewswire - October 6th, 2024
- Its going to be ubiquitous: Weight loss drugs may aid rheumatic disease treatment - Healio - October 6th, 2024
- Comorbidities Associated With Psoriasis: 5 Things to Know - Medscape - October 6th, 2024
- Opinion: Let's treat arthritis with the seriousness it deserves - Vancouver Sun - October 6th, 2024
- New handheld scanner technology could transform cancer and arthritis diagnosis - The Engineer - October 6th, 2024
- Stem cell therapy for osteoarthritis: Functional cartilage regeneration using 3d bioprinting technology - Open Access Government - October 6th, 2024
- Handheld scanner could transform cancer and arthritis diagnosis study - The Independent - October 6th, 2024
- Ankylosing Spondylitis and Self-Care: 6 Science-Backed Tips - Everyday Health - October 6th, 2024
- From a Labrador with arthritis to a goldfishs lifespan your pet queries answered... - The Sun - October 6th, 2024
- 15 Home Essentials That Make Life Easier If You Have Arthritis - HuffPost - September 21st, 2024
- Gout, a painful form of arthritis, is on the rise. Avoiding red meat and alcohol can help. - Yahoo Life - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pain - MedicineNet - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - U.S. News & World Report - September 21st, 2024
- Arthritis can flare up in colder weather: Tips to easing the pan - Medical Xpress - September 21st, 2024
- See how Waymo is bringing Arthritis Foundation of Arizona families to the ballpark - ABC15 Arizona in Phoenix - September 21st, 2024
- Prevalence of Loneliness in Inflammatory Arthritis and its Association with Disease Activity - Physician's Weekly - September 21st, 2024
- Psoriatic Arthritis and Gluten: Whats the Link? - Health Central - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - Southernminn.com - September 21st, 2024
- 6 Knee Injuries That Can Cause Arthritis - Health News Hub - September 21st, 2024
- The Best Rheumatoid Arthritis Self-Care Tips To Soothe Painful Joints and Improve Mobility - Yahoo Life - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - El Paso Inc. - September 21st, 2024
- Shifting kneecap in kids? Early ligament repair can prevent arthritis in young Age: Experts - The Times of India - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - Shelbynews - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - Citizentribune - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - News-Daily.com - September 21st, 2024
- Casavant: Access to virtual care at risk for millions of arthritis patients - Daily Independent - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - Avery Journal Times - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - The Elkhart Truth - September 21st, 2024
- What To Eat (And Skip) on a Rheumatoid Arthritis Diet To Reduce Painful Inflammation - Woman's World - September 21st, 2024
- Tiny knee bone linked to arthritis may have helped humans walk upright, scientists suggest - Sky News - September 13th, 2024
- Medical Marijuana Helps People With Arthritis And Other Rheumatic Conditions Reduce Use Of Opioids And Other Medications, Study Shows - Marijuana... - September 13th, 2024
- My 'stomach bug' turned out to be an agonising pain condition that left me wheelchair bound within four years - Daily Mail - September 13th, 2024
- Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis - Nature.com - September 13th, 2024